Skip to content

Trevor Millar

Ambio Life Sciences, Vancouver, British Columbia, Canada.

3 papers in the library · 99 citations · publishing 2016-2024

Papers

Magnesium-ibogaine therapy in veterans with traumatic brain injuries.

Nature medicine February 1, 2024 Kirsten N Cherian, Jackob N Keynan, Lauren Anker et al. 66 citations

A combination of the plant-derived compound ibogaine with magnesium, given alongside complementary treatments, led to large improvements in functioning, PTSD, depression, and anxiety in 30 male Special Operations Forces veterans with mild traumatic brain injury. Functioning improved significantly both immediately after treatment and one month later, with very large effects on PTSD, depression, and anxiety at one month. No serious adverse events occurred. The authors call for controlled trials to confirm these initial open-label findings.

Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report.

Journal of psychoactive drugs January 1, 2016 Laurie Cloutier-Gill, Evan Wood, Trevor Millar et al. 22 citations

A 37-year-old woman with a 19-year history of severe opioid use disorder, who had never achieved more than two months of continuous abstinence while on methadone, maintained an ongoing 18-month period of abstinence after a four-day ibogaine treatment. No safety issues were observed. The authors suggest that ibogaine may produce transformative experiences that lead to long-term remission in some treatment-refractory patients, but rigorous trials are needed to establish safety and efficacy.

Novel treatment of opioid use disorder using ibogaine and iboga in two adults

Journal of Evolutionary Psychology March 30, 2020 Claire Wilson, Trevor Millar, Zak Matieschyn 11 citations

Ibogaine, a naturally occurring psychedelic medicine, may help treat opioid use disorder by reducing withdrawal symptoms and supporting abstinence. A case series of two individuals who accessed ibogaine through unregulated clinics in Vancouver found that one client achieved total abstinence from all opioids within 5–6 days of starting treatment, experienced no withdrawal symptoms, and remained abstinent for 3 years. The second patient stopped non-medical opioids after the first treatment and used ibogaine to reduce opioid agonist therapy, maintaining abstinence for 2 years. The psychoactive experience may also help realign values and reduce depression, though further studies are needed to establish safety and efficacy.